The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

Ryoncil is part of a development programme for inflammatory diseases such as SR-aGvHD in adults, and biologic-res ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...

US FDA approves Mesoblast’s mesenchymal stromal cell therapy, Ryoncil for steroid-refractory aGvHD in children 2 months and older: Melbourne, Australia Monday, December 23, 2024 ...

The FDA has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute GVHD in pediatric patients age 2 months and older.

Mesoblast (ASX:MSB) has received approval from the US Food and Drug Administration (FDA) for Ryoncil (remestemcel-L), making ...

Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...